Literature DB >> 15528263

In vitro oocyte maturation for the treatment of infertility associated with polycystic ovarian syndrome: the French experience.

A Le Du1, I J Kadoch, N Bourcigaux, S Doumerc, M-C Bourrier, N Chevalier, R Fanchin, R-C Chian, G Tachdjian, R Frydman, N Frydman.   

Abstract

BACKGROUND: In vitro oocyte maturation (IVM) permits the use of immature oocytes in IVF. IVM does not require ovarian stimulation and so can be offered to patients at risk of ovarian hyperstimulation syndrome.
METHODS: For this indication, we carried out 45 cycles of IVM in 33 women with polycystic ovarian syndrome (PCOS).
RESULTS: A total of 509 cumulus-oocyte complexes was obtained; 276 (54.2%) oocytes matured in 24 h and 45 (8.8%) in 48 h. The normal fertilization (2PN) rate of oocytes matured in 24 and 48 h was 69.5 and 73.3% respectively. Among the 214 embryos obtained, 103 were transferred and 30 were frozen. Forty transfers were performed (2.5 embryos/transfer). Eleven women had a positive beta-hCG test (26.2% of pregnancies/puncture, 27.5% of pregnancies/transfer) and nine women had a clinical pregnancy (20.0% of pregnancies/puncture, 22.5% of pregnancies/transfer). Five babies have been born and one pregnancy is ongoing. Results of the clinical examination carried out at birth were normal.
CONCLUSIONS: Our results show that IVM may be offered as an alternative to conventional IVF and to ovarian drilling in women with PCOS. The role of IVM in the therapeutic armamentarium for this condition should be further clarified.

Entities:  

Mesh:

Year:  2004        PMID: 15528263     DOI: 10.1093/humrep/deh603

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  30 in total

1.  Fertilization outcome, embryo development and birth after unstimulated IVM.

Authors:  Adriana Bos-Mikich; Marcelo Ferreira; Marcos Höher; Gerta Frantz; Norma Oliveira; Caroline G Dutra; Nilo Frantz
Journal:  J Assist Reprod Genet       Date:  2010-10-06       Impact factor: 3.412

2.  In-vitro maturation of human oocytes: before or after vitrification?

Authors:  Giovanna Fasano; Isabelle Demeestere; Yvon Englert
Journal:  J Assist Reprod Genet       Date:  2012-04-04       Impact factor: 3.412

3.  Successful pregnancy following a novel endometrial preparation in a PCOS patient undergoing IVM: a case report.

Authors:  Maryam Eftekhar; Mohammad Ali Khalili; Abbas Aflatoonian; Navid Esfandiari
Journal:  J Assist Reprod Genet       Date:  2012-02-18       Impact factor: 3.412

4.  Maturation, fertilization, and the structure and function of the endoplasmic reticulum in cryopreserved mouse oocytes.

Authors:  Katie M Lowther; Vanessa N Weitzman; Donald Maier; Lisa M Mehlmann
Journal:  Biol Reprod       Date:  2009-03-18       Impact factor: 4.285

Review 5.  Controversies in IVM.

Authors:  Shauna Leigh Reinblatt; Weon-Young Son; Einat Shalom-Paz; Hananel Holzer
Journal:  J Assist Reprod Genet       Date:  2011-05-10       Impact factor: 3.412

6.  Anti-mullerian hormone as a predictive marker for the selection of women for oocyte in vitro maturation treatment.

Authors:  Rubens Fadini; Ruggero Comi; Mario Mignini Renzini; Giovanni Coticchio; Marilena Crippa; Elena De Ponti; Mariabeatrice Dal Canto
Journal:  J Assist Reprod Genet       Date:  2011-06-15       Impact factor: 3.412

Review 7.  In vitro growth and maturation of mouse oocyte-granulosa cell complex from cryopreserved ovaries and achievement of pup birth.

Authors:  Akiko Hasegawa; Koji Koyama
Journal:  Reprod Med Biol       Date:  2007-05-14

8.  Natural cycle IVF/IVM may be more desirable for poor responder patients after failure of stimulated cycles.

Authors:  Jianhua Li; Ye Xu; Guoping Zhou; Junhong Guo; Nan Xin
Journal:  J Assist Reprod Genet       Date:  2011-06-22       Impact factor: 3.412

9.  Spontaneous in vitro maturation of oocytes prior to ovarian tissue cryopreservation in natural cycles of oncologic patients.

Authors:  María-José Escribá; Noelia Grau; Laura Escrich; Edurne Novella-Maestre; María Sánchez-Serrano
Journal:  J Assist Reprod Genet       Date:  2012-09-11       Impact factor: 3.412

10.  What is the optimal threshold of serum Anti-Müllerian hormone (AMH) necessary for IVM treatments?

Authors:  Alon Kedem; Gil M Yerushalmi; Ettie Maman; Rina Hemi; Mirit Hanochi; Ariel Hourvitz
Journal:  J Assist Reprod Genet       Date:  2013-04-23       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.